Research Funded

Elimination of Macrophages to Improve T cell Therapy in Synovial Sarcoma

Seth Pollack, MD, Fred Hutchinson Cancer Research Center
Recipient of the: Bud Lawall Memorial Research Award

Abstract: Synovial Sarcoma is a soft tissue sarcoma subtype with poor outcomes in the advanced setting. Although it is immunologically “cold,” it generally expresses the highly immunogenic protein NY-ESO-1. Although NY-ESO-1 has... Read More

Modeling, Characterizing, and Targeting Aggressive, STAG2-mutated Ewing Sarcoma

Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center
Recipient of the: Catherine Malatesta Memorial Research Award

Abstract: Loss of function mutations of STAG2 occur in 10-15% of Ewing sarcoma (ES) patients. This is clinically significant, as loss of STAG2 is associated with poor clinical outcomes. STAG2 encodes a protein that is central to the... Read More

BMI1 as a Novel Driver and Target in Alveolar Rhabdomyosarcoma

Robert Schnepp, MD, PhD, Emory University - Winship Cancer Institute
Recipient of the: Derek G. Schnapp Memorial Research Award

Abstract: Despite significant efforts within oncology, effective therapies for alveolar rhabdomyosarcoma (ARMS) remain unrealized. Patients with ARMS are treated with intensive multimodal therapy, but outcomes still remain unaccepta... Read More

Global impact of the DNA/RNA helicase DHX9 on the processing of coding and noncoding transcripts in Ewing sarcoma pathogenesis

Maria Paola Paronetto, PhD, IRCCS Santa Lucia Foundation
Recipient of the: Pittsburgh Cure Sarcoma Research Award

Abstract: Ewing Sarcomas (ES) are biologically aggressive tumors of bone and soft tissues, characterized by in frame chromosomal translocation leading to the expression of the EWS-FLI1 oncogene. They affect mainly children and adole... Read More

Clinical Evaluation of BET and HDAC Inhibition in Canine Sarcoma

Tzipora Eisinger, PhD, University of Pennsylvania
Recipient of the: Race to Cure Sarcoma Research Award

Abstract: Targeting chromatin-remodeling enzymes holds great promise for treating soft tissue sarcomas (STS) since 1) the key oncogenic drivers in many sarcomas are translocation-derived chimeric transcription factors whose activiti... Read More

Plexin-Semaphorin: a new signaling axis in Sarcomas

Charles Keller III, MD, Children's Cancer Therapy Development Institute
Recipient of the: Race to Cure Sarcoma Research Award

Abstract: The Plexin-Semaphorin pathway is previously unexplored as a target in sarcomas but may play a central role in the progression of the soft tissue sarcoma, rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sa... Read More